Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, Arnould L, Beltjens F, Desmoulin I, Mayeur D, Kaderbhai C, Hennequin A, Jankowski C, Padeano MM, Costaz H, Amet A, Coutant C, Coudert B, Bertaut A, Ladoire S.
Ilie SM, et al.
Breast Cancer. 2023 Nov;30(6):997-1007. doi: 10.1007/s12282-023-01490-1. Epub 2023 Aug 10.
Breast Cancer. 2023.
PMID: 37561255
Free PMC article.